RESEARCH TRIANGLE PARK, N.C. - October 4, 1999 - Quintiles Transnational Corp. (Nasdaq: QTRN) today announced the acquisition of Medicines Control Consultants Pty Ltd. (MCC), a South Africa-based pharmaceutical regulatory consulting group.

Based in Pretoria, MCC is the largest company in South Africa providing contract regulatory services to both local and international customers. MCC has expertise in regulatory affairs and Good Manufacturing Practice (GMP), including consulting on sourcing, manufacturing, packaging and distribution.

MCC is managed by Nerine Kraamwinkel and Allison Vienings, both of whom previously worked for the Medicines Control Council, the South African agency that regulates pharmaceutical products. MCC currently employs 10 full-time pharmacists with specialized expertise in regulatory affairs and five regulatory consultants who work exclusively for the company.

The acquisition will be accounted for as a purchase and is expected to be neutral to Quintiles' earnings per share. MCC will be integrated into the Quintiles Product Development service group, which provides worldwide biological, drug and device development services focused on accelerating product success.

"The regulatory affairs knowledge of MCC is going to be an important asset to Quintiles in the fast-changing South Africa regulatory environment," said Ludo Reynders, Ph.D., Chief Executive Officer of Quintiles Product Development. "We see significant potential outside the product development field for our commercialization business to work with MCC on product licensing opportunities.

"The acquisition of MCC complements and strengthens Quintiles Clindepharm, Quintiles ClinData and Quintiles Niehaus & Botha, giving us the capability to offer a full product development service in South Africa."

Kraamwinkel, who founded MCC in 1985, said: "We believe MCC has an excellent reputation among companies based in South Africa, the United States, Europe, the Indian subcontinent and elsewhere in the world. Joining Quintiles offers the exciting prospect of real synergies arising between our product licensing activities and Quintiles' commercialization operations."

Quintiles Transnational Corp. is the market leader in providing a full range of integrated product development and commercialization solutions to the pharmaceutical, biotechnology and medical device industries. Quintiles also is a leader in electronic transactions processing and informatics for the healthcare sector and provides healthcare policy consulting to governments and other organizations worldwide.

Headquartered near Research Triangle Park, North Carolina, Quintiles is a member of the Forbes Platinum 400, the Fortune 1000, the Business Week Global 1000, the Nasdaq-100 Index, and the Fortune 100 List of Fastest-Growing Companies. With more than 19,000 employees worldwide and offices in 31 countries, Quintiles operates through specialized work groups dedicated to meeting customers' individual needs.

Information in this press release contains "forward-looking statements." These statements involve risks and uncertainties that could cause actual results to differ materially, including without limitation, the ability of the recently combined businesses to be integrated with Quintiles' current operations, actual operating performance, the ability to operate successfully in new lines of business, the ability to maintain large client contracts or to enter into new contracts, and the actual costs of combining the businesses. Additional factors that could cause actual results to differ materially are discussed in the company's recent filings with the Securities and Exchange Commission, including but not limited to its S-3 and S-4 Registration Statements, its Annual Report on Form 10-K, its Form 8-Ks, and its other periodic reports, including Form 10-Qs.